A study of the chemical and biological stability of vasoactive intestinal peptide

被引：13

作者：

Cui, Xu ^{[1
]}

Cao, Deying ^{[1
]}

Qu, Changhai ^{[2
]}

Zhang, Xiaoyan ^{[3
]}

Zheng, Aiping ^{[3
]}

机构：

[1] Hebei Med Univ, Coll Pharmaceut Sci, Shijiazhuang, Peoples R China

[2] Beijing Univ Chinese Med, Sch Pharm, Beijing, Peoples R China

[3] Beijing Inst Pharmacol & Toxicol, Dept Pharmaceut, Beijing, Peoples R China

来源：

DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY | 2013年 / 39卷 / 12期

关键词：

Vasoactive intestinal peptide; stability; artificial gastric fluid; artificial intestinal fluid; oral administration; BRAIN; VIP;

D O I：

10.3109/03639045.2012.693503

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Context: Vasoactive intestinal peptide (VIP) is a linear cationic neuropeptide composed of 28 amino acids. It belongs to the glucagon/secretin family. The biological functions of VIP are relatively broad, but it has not been well studied in the field of pharmaceutics. Especially in the selection of the way of VIP administration and the pharmaceutical formulation, the theory basis was deficient appreciably. Objective: To provide the theory basis for the pharmaceutical development of VIP, the chemical and biological stability of VIP was studied. Materials and methods: The stability of VIP in different pH values, ionic strength, temperature, artificial gastric fluid and artificial intestinal fluid was investigated, and the concentration of VIP was calculated by HPLC method. Results: The stability of VIP was pH-dependent. VIP was stable in acid and neutral solution, and almost didn't degrade during pH <= 7 solution. However, it was instability in basic solution and degraded completely at 30 min in pH 13 solution. Ionic strength did not affect its stability. VIP was stable in freezing conditions but it degraded at low concentration in cold storage. Furthermore, VIP degraded so quickly in artificial gastric fluid and artificial intestinal fluid that it can't be detected at 0 min. Discussion and conclusion: the chemical and biological characteristic of VIP was unstable, so it isn't suitable for oral administration.

引用

页码：1907 / 1910

页数：4

共 6 条

[1] VIP neurotrophism in the central nervous system: Multiple effectors and identification of a femtomolar-acting neuroprotective peptide [J].

Brenneman, DE ;

Glazner, G ;

Hill, JM ;

Hauser, J ;

Davidson, A ;

Gozes, I .

VIP, PACAP, AND RELATED PEPTIDES: THIRD INTERNATIONAL SYMPOSIUM, 1998, 865 :207-212

[2] Passage of vasoactive intestinal peptide across the blood-brain barrier [J].

Dogrukol-Ak, D ;

Banks, WA ;

Tuncel, N ;

Tuncel, M .

PEPTIDES, 2003, 24 (03) :437-444

[3] Glucose-targeted niosomes deliver vasoactive intestinal peptide (VIP) to the brain [J].

Dufes, C ;

Gaillard, F ;

Uchegbu, IF ;

Schätzlein, AG ;

Olivier, JC ;

Muller, JM .

INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2004, 285 (1-2) :77-85

[4] Liposomal vasoactive intestinal peptide [J].

Sethi, V ;

Önyüksel, H ;

Rubinstein, I .

LIPOSOMES, PT E, 2005, 391 :377-395

[5] Liposomal vasoactive intestinal peptide for lung application: Protection from proteolytic degradation [J].

Stark, Brigitte ;

Andreae, Fritz ;

Mosgoeller, Wilhelm ;

Edetsberger, Michael ;

Gaubitzer, Erwin ;

Koehler, Gottfried ;

Prassl, Ruth .

EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2008, 70 (01) :153-164

[6] Association of vasoactive intestinal peptide with polymer-grafted liposomes: Structural aspects for pulmonary delivery [J].

Stark, Brigitte ;

Debbage, Paul ;

Andreae, Fritz ;

Mosgoeller, Wilhelm ;

Prassl, Ruth .

BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2007, 1768 (03) :705-714

← 1 →